Press Releases

Read our latest announcements

Filter by year:

2018-07-13
Modus Therapeutics completes a SEK 140m financing led by HealthCap

Funds to be used to continue the clinical development of sevuparin for sickle cell disease

View Press Release
2018-04-18
Sevuparin receives Rare Pediatric Disease Designation from FDA for the treatment of children with sickle cell disease

STOCKHOLM, SWEDEN – 18 April 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), has announced that sevuparin for the treatment of SCD was granted rare pediatric disease designation by the US Food & Drug Administration (FDA). Sickle cell disease, […]

View Press Release
2018-03-15
Dr. John Öhd appointed Chief Medical Officer at Modus Therapeutics

STOCKHOLM, SWEDEN –15 March 2018: Modus Therapeutics AB, a company developing innovative treatments in disease areas with high unmet medical needs with a focus on sickle cell disease (SCD), announces the appointment of Dr. John Öhd as the Company’s Chief Medical Officer (CMO). Dr. Öhd joins Modus from Medivir AB, where he was CMO and […]

View Press Release
2018-03-09
Notice of extraordinary General Meeting in Modus Therapeutics Holding AB (Publ)

The shareholders in Modus Therapeutics Holding AB (publ), reg. no. 556851-9523 (the “Company”), are hereby invited to attend the extraordinary general meeting to be held in the offices of Setterwalls Advokatbyrå, Sturegatan 10 in Stockholm, on 23 March 2018 at 10:00 a.m. Conditions for participation Shareholders who wish to attend the meeting shall be entered in […]

View Press Release
2018-01-05
Modus Therapeutics to Present at Biotech Showcase 2018 in San Francisco

STOCKHOLM, SWEDEN – 5 January, 2018. Modus Therapeutics AB, a company focused on innovative treatments for patients with sickle cell disease (SCD), today announces that CEO Ellen K. Donnelly will present at the 10th Annual Biotech Showcase held in San Francisco (CA, United States) from January 8 – 10, 2018. Presentation details are as follows: […]

View Press Release